Compare Organon & Co. Common Stock (OGN) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Atlassian Corporation PLC — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Atlassian Corporation PLC trades at $202 (market cap $52.66B). The key difference: Atlassian Corporation PLC is far larger — about 14.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Atlassian Corporation PLC for 65 Days on average.
| OGN | TEAM | |
|---|---|---|
Market Cap | $3.62B | $52.66B |
Volume | 2,892,999 | 2,601,329 |
Sector | Health | Technology |
52-Week High | $13.81 | $208.04 |
52-Week Low | $5.70 | $57.15 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $11.04B | $52.66B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Atlassian (TEAM) trades at $204.66, down 1.49% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong revenue growth, improving net losses, and consistent earnings beats, though profitability metrics remain negative. Recent news highlights AI-driven growth catalysts and cloud momentum.
The outlook is positive given analyst consensus and AI adoption, but high valuation ratios and persistent net losses pose risks. Upside is supported by a large addressable market and subscription growth, while competition and execution challenges are key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
